CYTK · Cytokinetics, Incorporated
$81.92
-0.33% last session
End-of-day data · updated 2026-07-25
Market cap
$11B
Enterprise value
$11B
Trailing P/E
—
Forward P/E
-17.2
Dividend yield
—
Beta
0.42
Avg volume
3M
Employees
1K
2D change
-1.44%
5D change
2.06%
10D change
-2.28%
30D change
-0.07%
60D change
5.83%
MTD change
-5.30%
YTD change
27.07%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CYTK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-07
Latest call per bank · past 12 months
RBC Capital
Outperform$117
+42.8% vs priceUBS
Buy$115
+40.4% vs priceCitigroup
Buy$99.00
+20.8% vs priceJP Morgan
Overweight$97.00
+18.4% vs priceWells Fargo
Overweight$105
+28.2% vs priceMorgan Stanley
Overweight$103
+25.7% vs priceBarclays
Overweight$95.00
+16.0% vs priceGoldman Sachs
Buy$95.00
+16.0% vs priceBank of America
Neutral$56.00
-31.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-07 | RBC Capital | Maintains | Outperform | $119 → $117 |
| 2026-06-29 | UBS | Upgrade | Neutral → Buy | $69.00 → $115 |
| 2026-06-24 | Mizuho | Maintains | Outperform | $100 → $118 |
| 2026-06-17 | Needham | Reiterates | Buy | $102 |
| 2026-05-19 | Citigroup | Initiates | Buy | $0.00 → $99.00 |
| 2026-05-12 | JP Morgan | Maintains | Overweight | $92.00 → $97.00 |
| 2026-05-11 | HC Wainwright & Co. | Maintains | Buy | $136 → $140 |
| 2026-05-07 | Wells Fargo | Maintains | Overweight | $95.00 → $105 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 4.7% above the 50-day MA ($78.21).
- Price vs 200-day MA: Trading 21.6% above the 200-day MA ($67.36).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.68) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($33.23) and high ($87.26).
CYTK Price Chart
Loading chart for CYTK…
Fundamentals
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.